Empty Link Skip to Content

Matheson LLP Advises Horizon Therapeutics plc on its Proposed $28 Billion Acquisition by Amgen Inc.

A Matheson team led by Corporate M&A Partners David Fitzgibbon and New York based Partner David Jones, together with Corporate M&A Senior Associate Susan Carroll Chrysostomou and Corporate M&A Associates Thomas Burke, Julia Helmore, Sinead Loughran and Leo Collins alongside Partners Niall Collins and Calum Warren (Antitrust), Matthew Broadstock and Tomás Bailey (Tax), Carlo Salizzo (IP and Data Protection) and Patrick Molloy and Senior Associate Conor Lynch (Finance) are advising Horizon Therapeutics plc on all aspects of its proposed acquisition by Amgen Inc., to be implemented via an Irish law scheme of arrangement

The acquisition, structured as an all-cash offer with a value of approximately $28 billion, has been announced today.  With its focus on the research development and commercialisation of medicines for rare, autoimmune and severe inflammatory diseases, Horizon's acquisition by Amgen Inc. will further accelerate the impact of Horizon’s medicines globally and reinforce the continued long-term growth of the firm.

Speaking today, David Fitzgibbon of Matheson LLP said “it has been an honour to work with Tim Walbert, Sean Clayton and the rest of the Horizon team on this milestone transaction for Horizon and its business. As Ireland's largest law firm Matheson's involvement in this transaction emphasises our position as the market-leader in large cap cross border M&A.”

For more information about our legal services, please contact a member of the Corporate team or your usual Matheson contact.